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Abstract
Background: Mucopolysaccharidosis type II, an X-linked recessive disorder is the most common lysosomal storage
disease detected among Filipinos. This is a case series involving 23 male Filipino patients confirmed to have Hunter
syndrome. The clinical and biochemical characteristics were obtained and mutation testing of the IDS gene was
done on the probands and their female relatives.
Results: The mean age of the patients was 11.28 (SD 4.10) years with an average symptom onset at 1.2 (SD 1.4)
years. The mean age at biochemical diagnosis was 8 (SD 3.2) years. The early clinical characteristics were
developmental delay, joint stiffness, coarse facies, recurrent respiratory tract infections, abdominal distention and
hernia. Majority of the patients had joint contractures, severe intellectual disability, error of refraction, hearing loss
and valvular regurgitation on subspecialists’ evaluation. The mean GAG concentration was 506.5 mg (SD 191.3)/
grams creatinine while the mean plasma iduronate-2-sulfatase activity was 0.86 (SD 0.79) nmol/mg plasma/4 h.
Fourteen (14) mutations were found: 6 missense (42.9%), 4 nonsense (28.6%), 2 frameshift (14.3%), 1 exon skipping
at the cDNA level (7.1%), and 1 gross insertion (7.1%). Six (6) novel mutations were observed (43%): p.C422F, p.
P86Rfs*44, p.Q121*, p.L209Wfs*4, p.T409R, and c.1461_1462insN[710].
Conclusion: The age at diagnosis in this series was much delayed and majority of the patients presented with
severe neurologic impairment. The results of the biochemical tests did not contribute to the phenotypic
classification of patients. The effects of the mutations were consistent with the severe phenotype seen in the
majority of the patients.
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Background
Mucopolysaccharidosis type II (Hunter Syndrome) is an
X-linked disorder with an incidence of 0.3–0.71 per
100,000 live births [1]. In the Philippines, there is no re-
ported incidence of Hunter syndrome. Forty two pa-
tients have been recorded in the lysosomal storage
disease registry of the Institute of Human Genetics-
National Institutes of Health, Manila since 1999. The
disorder is caused by a deficiency in the lysosomal en-
zyme iduronate-2-sulfatase (I2S), leading to an accumu-
lation of the glycosaminoglycans dermatan sulfate and
heparan sulfate [2]. The IDS gene is located in Xq28,
spans 24 kb and contains 9 exons. An IDS-like pseudo-
gene comprised of copies of exons 2 and 3 and intron 7
is located about 20 kb from the active gene [2].
Patients with the disease are classified as having the
severe, intermediate or attenuated forms, depending on
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the degree of mental retardation present. The severe
form appears between 2 and 4 years of age and is char-
acterized by progressive neurologic and somatic involve-
ment. Death usually occurs in the first or second decade
of life mostly due to the cardiopulmonary complications.
A milder form of Hunter syndrome is characterized by
preservation of intelligence and survival into adulthood
but with obvious somatic involvement [2]. Patients clas-
sified as intermediate usually have mild to moderate
learning difficulties and less severe skeletal disease [3].
Analysis of urine glycosaminoglycans (GAGs) can be
used to confirm the suspicion of Hunter syndrome. Ex-
cess urinary excretion of dermatan sulfate and heparan
sulfate is characteristic of Hunter syndrome but not
diagnostic as these GAGs can also be elevated in other
types of mucopolysaccharidoses. Thus, measurement of
iduronate-2-sulfatase enzyme activity is necessary to
confirm the diagnosis. Absent or low I2S activity in
males is diagnostic of Hunter syndrome but absolute en-
zyme activity cannot be used to predict the severity of
the phenotype [1].
Genetic testing of the iduronate-2-sulfatase gene (IDS)
may allow prediction of the phenotype. It is also the only
reliable way to identify female carriers of the disease which
is a critical factor in family planning decisions [4]. Muta-
tions identified in the patients included large alterations
and small gene alterations which further confirmed the
extreme heterogeneity of IDS gene alterations, as more
than 350 have been reported to date [5, 6].
This study is the first attempt to characterize the clin-
ical, biochemical and molecular characteristics of
Filipino patients with Hunter syndrome and aims to de-
scribe the phenotype and genotype aspects of the
disease.
Methods
Study design and participants
This is a case-series of patients aged 1–21 years old who
were diagnosed at the Philippine General Hospital
(PGH) or Institute of Human Genetics (IHG) between
1999 and 2015 and listed in the Lysosomal Storage Dis-
ease Registry of the Institute of Human Genetics, Na-
tional Institutes of Health, the only institution in the
Philippines providing genetic services. Written informed
consent from the parents and/or patients was obtained
prior to participation. Patients had a clinical diagnosis of
Hunter syndrome which was further confirmed bio-
chemically by demonstrating a high excretion of glycos-
aminoglycans in the urine and a deficiency in iduronate-
2-sulfatase activity in leukocytes. The mothers and other
female members of the family of the patients who con-
sented also underwent mutation studies. Pedigree ana-
lysis was done in each family and genetic counseling was
provided after confirmation of the diagnosis. The study
protocol was approved by the institution’s ethical review
board (2012-329-01).
Clinical characteristics
The data on the age at onset of symptoms, age at diag-
nosis, early clinical signs and symptoms as well as their
developmental histories were obtained from the medical
records of the Philippine General Hospital. The patients
were also asked to come for clinic evaluations where med-
ical specialists assessed the patients’ general appearance
and determined any skeletal, ophthalmologic, otorhinolar-
yngologic, gastrointestinal, cardiovascular, pulmonary and
neurologic abnormalities.
Despite the lack of a standardized scoring index of se-
verity for patients with Hunter syndrome, in this series,
the severity of the neurologic disease was used to arrive
at a particular form of classification. They were classified
according to the following by the clinical geneticists tak-
ing care of them: severe if the patients had moderate to
severe intellectual disability and or neurodegeneration;
intermediate if they had mild intellectual disability or
learning difficulties; and attenuated if they had no behav-
ioral disturbance or mental retardation regardless of the
severity of bone and visceral involvement [3, 5] In terms
of intellectual disability, the patients’ adaptive functions
were categorized by the developmental pediatricians
who attended to them in the clinic based on the DSM 5
(Diagnostic and Statistical Manual for Mental Disorders)
criteria for developmental quotient (DQ of 50–70: mild
intellectual disability; DQ 35–50: moderate intellectual
disability; DQ of 20–35 severe intellectual disability and
DQ <20: profound intellectual disability).
Biochemical studies
All 23 patients in the study had urinary glycosaminogly-
cans and plasma IDS activity measurements on their leu-
kocytes. These tests were sent to the laboratory of the
National Taiwan University Hospital. The concentration
of urinary glycosaminoglycans was measured using the
Dimethylene Blue assay in relation to urinary creatinine.
The results were compared with the established refer-
ence ranges per age group of urinary GAGs per grams
of creatinine. The plasma IDS activity was measured
using the 4-methylumbelliferone (4-MU) fluorometric
enzyme assay.
Mutation studies
The peripheral blood from the patients underwent DNA
extraction using the QIAgen QIAamp Blood Midi kit.
The coding region of the IDS gene was amplified using
both previously described and newly designed oligo-
nucleotide primers. Bi-directional Sanger sequencing of
nine exon-specific amplicons containing flanking in-
tronic regions was performed using the ABI 3130
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Genetic Analyzer [3, 7]. Nested PCR was specifically
done for the amplification of exon 3 to avoid co-
amplification of a homologous region in the IDS pseudo-
gene. Mutation confirmation and heterozygote detection
were subsequently performed by sequencing the IDS
genomic amplicons containing the identified mutation
using DNA obtained from possible carriers.
Where PCR amplification of exon 8 using genomic
DNA failed, RNA was extracted from 2.5 ml of whole
blood using the PreAnalytiX PAXgene Blood RNA kit,
then subsequently applied as template in cDNA synthe-
sis using Invitrogen M-MLV Reverse Transcriptase. A
forward primer within exon 7 and a reverse primer
within exon 9 were designed to detect the exon 8 dele-
tion through gap PCR. Confirmation of the deletion was
carried out by sequencing the PCR product.
Methods of data analysis
The quantitative patient characteristics such as age at
diagnosis were summarized by means and standard devia-
tions (SDs). The qualitative characteristics such as general
appearance, skeletal abnormalities, and other organ com-
plications were presented as a frequency distribution.
Results
Clinical findings
A total of 23 male patients belonging to 21 families par-
ticipated in the study. The mean age of the patients at
the time of the study was 11.28 (SD 4.10) years and the
mean age at onset of symptoms reported for 20 patients
was 1.2 (SD 1.43) years ranging from as early as the day
of birth to as late as 6 years of age. The onset for the
other three patients was reported as ‘less than 1 year of
age’. Two of these patients had umbilical hernia at birth.
The mean age at biochemical diagnosis was 7.6 (SD
3.58) years. The earliest age that the diagnosis was con-
firmed biochemically was 7 months and the latest was
13.5 years. There were four patients in this study who
belonged to two sets of families.
The mean weight at the time of evaluation was 23 (SD
3.6) kg, mean height was 114.5 (SD 9.7) cm and mean
head circumference was 54 (SD 2.1) cm. There was a
slight increase in weight as the patients grew in age
(Fig. 1) but the pattern for height showed a flatter line as
they grew older (Fig. 2). The head circumference was in-
creasing as the patient got older (Fig. 3).
The early clinical characteristics observed by the par-
ents were developmental delay (21/23; 91.3%), followed
by joint stiffness and coarse facies (20/23; 87%), recur-
rent upper respiratory tract infections (18/23; 78.3%), ab-
dominal distention and hernia (14/23; 61%) and
recurrent ear infections (6/23; 26%) (Fig. 4). The parents
also recalled that their sons were told by physicians dur-
ing the course of the disease to have hepatosplenome-
galy (9/23; 39%), airway obstruction (9/23; 39%), papular
rash (6/23; 26%), kyphoscoliosis (4/23; 17%), valvular
thickness (4/23; 17%), papilledema (3/23; 13%) and hip
dysplasia (1/23; 4%).
On subspecialists’ evaluations (Fig. 5), 52% (12/23)
presented with severe intellectual disability while 17%
(4/23) had moderate intellectual disability. Twenty-one
percent (5/23) had mild intellectual disability and 1 pa-
tient (4%) was developmentally and intellectually at par
with age upon formal developmental assessment at
9 years of age. One patient had global developmental
delay at 3 years old but the severity could not be
Fig. 1 Scatter plot of age and weight. Patients gained weight as they grew older
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determined yet at the time of evaluation. Based on this
neurodevelopmental assessment using the DSM 5 cri-
teria, 16 patients were classified as having the severe
phenotype (69.5%), five patients had the intermediate
phenotype (21.7%) and only one patient had the attenu-
ated phenotype. The boy who was found to have global
developmental delay at 3 years of age could not be clas-
sified to either severe or intermediate phenotype yet.
Unfortunately, majority of the patients were not com-
pletely assessed by brain imaging or electroencephalog-
raphy. Four patients (17.3%) were diagnosed to have
epilepsy but only one patient was able to undergo an
Fig. 2 Scatter plot of age and height. Patients’ heights flattened as they grew older
Fig. 3 Scatter plot of age and head circumference. Patients’ head circumference grew bigger as they got older
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electroencephalogram which revealed abnormal epilepti-
form discharges. One patient also had hydrocephalus on
computed tomography scan of the brain (4.3%). Carpal
tunnel syndrome was observed in 5 patients (22%), and
other symptoms that suggested a possible peripheral
neuropathy were seen in two patients (8.7%). One pa-
tient was diagnosed to have autism spectrum disorder.
Only 11 out of the 23 (48%) patients attended school at
the time of evaluation. None of the patients with severe
intellectual disability attended school.
Ophthalmologic findings showed error of refraction (12/
23; 52%), glaucoma, (5/23; 21.7%), and other eye findings
such as Meibomian gland dysfunction and pigmentary ret-
inopathy (5/23;21.7%). Hearing loss was profound in 4/23
(17.4%) patients, moderate to profound in 2 (8.7%), mod-
erate in 1 (4.3%) and unclassified in 4 (17.4%). Only five
patients were using hearing aids. Twelve patients had no
hearing loss at the time of this study (52.2%).
Hypertrophic tonsils were present in 9/23 patients
(39%). Obstructive sleep apnea was seen in nine patients
(39%) and another nine were suspected to have this dis-
order but did not undergo sleep studies yet. Bronchial
asthma was seen at 34.8% (8/23) and allergic rhinitis at
47.8% (11/23).
Fig. 4 Reported early clinical symptoms among Filipino patients with Hunter syndrome. The most common symptoms were developmental
delay, followed by joint stiffness, coarse facies, recurrent upper respiratory tract infections, abdominal distention and hernia and recurrent
ear infections
Fig. 5 Clinical characteristics of MPS II patients noted during subspecialists’ evaluations. More than half of the patients had intellectual disability,
joint stiffness and error of refraction
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Mild valvular regurgitation which involved the aortic
and mitral valves was noted at 47.8% (11/23) and left
ventricular dysfunction at 13% (3/23). Left ventricular
hypertrophy was seen in two patients (8.7%) and one pa-
tient was noted to have valvular thickness of the mitral
valve (4.3%).
Joint contractures were seen in 16 out of 23 patients
(69.57%). Only two patients had a skeletal survey done
which showed dysostosis multiplex (8.7%).
None of the patients ever received enzyme replace-
ment therapy for Hunter syndrome.
Biochemical findings
The mean GAG concentration for 22 patients was
506.5 mg (SD of 191.3) per grams creatinine. Majority of
the patients had GAG between 300 and 800 mg per
grams creatinine which were all beyond the average ref-
erence values for age across the different age groups
(<1 year old: 90.76 mg/grams creatinine; 3–5 years old:
45.16 mg/grams creatinine and >5 years old: 35.74 mg/
grams creatinine). The GAG analysis was not done for 1
patient with a severe type of disease.
The mean glycosaminoglycan (GAG) concentration
for patients with severe disease was 471.5 mg (SD 174.9)
per grams creatinine (range 126.1–778.6 mg/grams cre-
atinine); for those with intermediate type of the disease,
the mean was 534.2 mg (SD 86.8) per grams creatinine
(range 302.0–692.6) and the patient with attenuated dis-
ease had a GAG excretion of 443.7 mg per grams
creatinine. The patient with global developmental delay
whose phenotype could not be assessed yet had a GAG
excretion of 891.6 per grams creatinine. The GAG ana-
lysis that was performed did not include the amount of
the specific type of glycosaminoglycan excreted.
The plasma enzyme assay for iduronate-2-sulfatase ac-
tivity for those with a severe type of the disease had a
mean of 1.09 and a SD of 0.82 nmol/mg plasma/4 h. It
ranged from 0.01 to 3.02. For the intermediate type, the
mean was 0.45 (SD 0.36) nmol/mg plasma/4 h. It ranged
from 0.1 to 0.91. The patient with the attenuated type
had an activity of 0.01 nmol/mg plasma/4 h. The one
who had global developmental delay also had an enzyme
level of 0.01 nmol/mg plasma/4 h). Overall, the mean
plasma iduronate-2-sulfatase activity was 0.86 (SD 0.79)
nmol/mg plasma/4 h. As seen in Fig. 6, the distribution
of plasma iduronate 2 sulfatase activity was skewed indi-
cating that regardless of the phenotype, most had levels
of less than 1 nmol/mg/plasma/4 h.
Molecular characteristics
Studies on probands
Fourteen (14) different mutations were found in this
study among 23 patients belonging to 21 families
(Table 1). Six (6) were missense mutations (42.9%), 4
were nonsense (28.6%), 2 were frameshifts (14.3%), 1
was exon skipping at the cDNA level (7.1%), and 1 was a
gross insertion (7.1%). Most of the mutations were found
in exon 3 (36%). Previously reported mutations p.Q75*,
Fig. 6 Distribution of Iduronate-2-sulfatase (in nmol/mg/plasma/4 h) levels among 23 patients with Hunter syndrome. The distribution of plasma
iduronate 2 sulfatase activity was skewed indicating that regardless of the phenotype, most had levels of less than 1 nmol/mg/plasma/4 h
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p.P86L, p.R88H, p.W109*, p. R172*, p.R468Q, and
p.R468W were found. Six (6) novel mutations were ob-
served (43%). The novel mutation p.C422F was found in
3 patients who are siblings. The other novel mutations
found in unrelated patients were p.P86Rfs*44, p.Q121*,
p.L209Wfs*4, p.T409R, and c.1461_1462insN[710]. The
insertion of about 710 bp in exon 9 is yet to be fully
characterized. The length of the insertion was only esti-
mated by agarose gel electrophoresis (data not shown).
The mutations p. Q75*, p. P86L, and p.Q121* were
found to have occurred de novo.
Exon 8 skipping was identified in the cDNA of one pa-
tient. Complete deletion of exon 8 in the IDS transcript
had been previously reported. One case was caused by a
3254-bp deletion in genomic DNA from intron 7 to in-
tron 8 with an insertion of 20 bp [8]. Another case was
also caused by an extensive deletion of about 3 kb but
with a longer insertion of 157 bp [9]. However, it could
not be ascertained whether either of these was the same
as the mutation detected in this study since the deletion
breakpoints in the genomic DNA in our patient have
not yet been defined.
Most of the patients with moderate to severe cognitive
impairment or those belonging to the severe phenotype
had the following mutations: p.Q75*, p.P86Rfs*44,
p.R88H, p.W109*, p.Q121*, p.R172*, p.L209Wfs*4,
p.R468Q, p.R468W, Ex8del, and c.1461_1462insN[710].
Three patients presenting with severe phenotype were
not found to have any mutation in the exons examined.
Four patients presenting with mild learning difficulties
(intermediate phenotype) had the mutations p.W109*
(one patient) and p.C422F (three patients). One patient
with mild learning difficulties did not have any muta-
tions in the exons examined. The mutation p.W109* was
found in two patients who are first cousins, but one of
them presented with a severe phenotype and died at
12 years of age due to respiratory failure while the other
has only mild learning difficulties at 15 years of age. The
Table 1 Mutation studies of 23 patients with MPS II
Patient
No.
Mutation Consequence Location Phenotype Status Reference
P1 c.1265G > T p.C422F Exon 9 Intermediate novel -
P2 c.1265G > T p.C422F Exon 9 Intermediate novel -
P3 c.1265G > T p.C422F Exon 9 Intermediate novel -




Exon 8 Severe for further characterization at
genomic DNA level
-
P5 c.326G > A p.W109* Exon 3 Intermediate published Brusius-Facchin et al.,
2014 [20]
P6 none detected - - Severe - -
P7 c.1403G > A p.R468Q Exon 9 Severe published Whitley et al., 1993 [24]
P8 c.1403G > A p.R468Q Exon 9 Severe published Whitley et al., 1993 [24]
P9 c.326G > A p.W109* Exon 3 Severe published Brusius-Facchin et al.,
2014 [20]
P10 c.1403G > A p.R468Q Exon 9 Severe published Whitley et al., 1993 [24]
P11 none detected - - Severe - -
P12 c.[626delT; 629A > G] p.L209Wfs*4 Exon 5 Severe novel -
P13 c.1402C > T p.R468W Exon 9 Severe published Crotty et al., 1992 [23]
P14 c.223C > T p.Q75* Exon 2 Severe published, de novo Kato et al., 2005 [25]
P15 c.1461_1462insN[710] - Exon 9 Severe novel, for further characterization -
P16 none detected - - Severe - -
P17 c.263G > A p.R88H Exon 3 Severe published Rathmann et al., 1996
[22]
P18 c.(254_257)delC p.P86Rfs*44 Exon 3 Severe novel -
P19 none detected - - Intermediate - -
P20 c.1226C > G p.T409R Exon 9 Attenuated novel -
P21 c.361C > T p.Q121* Exon 3 Severe novel, de novo -
P22 c.257C > T p.P86L Exon 3 Global
developmental delay
published, de novo Popowska et al., 1995
[21]
P23 c.514C > T p.R172* Exon 5 Severe published Flomen et al., 1992 [27]
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mutation p.T409R was found in the lone patient with at-
tenuated phenotype who had normal cognition at 9 years
of age.
Family studies
Carrier testing done on 40 mothers and other female
members of each family showed that 20/40 (50%) were
carriers. Eleven of the 15 mothers (73%) tested were
found to be carriers. Three mothers whose children were
found to carry the missense mutations p.Q75*, p.P86L
and p.Q121* did not have the said mutations. Carrier
testing for exon 8 skipping showed inconclusive results
because the same shortened transcript represented by a
237-bp amplicon was also present in the control sample
from a healthy female, making the identification of true
carriers of genomic deletion of exon 8 uncertain (Fig. 7).
However, the band from the healthy control was notice-
ably fainter than the band from the patient’s mother
who is most probably a carrier of the genomic deletion.
The 237-bp amplicon isolated from the healthy control
had identical sequence with that of the patient’s. To
check for a contamination problem, RNA from another
healthy female was extracted then reverse transcribed
into cDNA separately, but the same gap PCR result per-
sisted. Whether a variant IDS transcript lacking exon 8
is actually produced in small quantities in healthy indi-
viduals remains to be clarified and further investigated.
Discussion
This is the first study done on the clinical, biochemical
and molecular characteristics of Filipino patients with
Hunter syndrome. Our data showed that the onset of
disease was early at a mean age of 1 year but the con-
firmation of diagnosis was done at a mean age of 7 years.
Therefore, it took an average of 6 years before the chil-
dren were diagnosed correctly and managed appropri-
ately. Despite the clinical features present among the
patients, late recognition and confirmation of the
diagnosis was a usual problem encountered in this
series. In the initial report from the Hunter Outcome
Survey (HOS) [10], the average age at diagnosis was
4 years of age. The delay in the diagnosis in our series
may be due to the lack of awareness among physicians
to recognize such constellation of features in one spe-
cific syndrome. A common pitfall when examining the
patient with undiagnosed Hunter syndrome is a failure
to link the many, seemingly unrelated signs and symp-
toms experienced by the patient into a single syndrome
[11]. Another reason could be the lack of facilities dedi-
cated for patients with rare diseases in the Philippines.
Similar to a study done in Brazil [10], the delay in the
diagnosis of patients with Hunter syndrome or any rare
metabolic disease in general could be mainly due to the
structure of the health system in the Philippines. Being
at the bottom of the government’s priority list, there are
very few health clinics and specialists that can compre-
hensively assess these types of patients.
The phenotypic expression of Hunter syndrome spans
a wide spectrum of clinical severity. If neurologic in-
volvement is the main basis of classification for the se-
verity of the disorder, it can be deduced that most of the
patients included in this study were skewed towards the
severe end of the spectrum as majority of them pre-
sented with moderate to severe intellectual disability. In
a worldwide Hunter Outcome Survey survey which
started in 2005, 84% of the 263 subjects enrolled in the
study showed neurologic involvement [12], verifying the
assumption that the severe phenotype may be more
prevalent than the attenuated phenotype [13].
The most common clinical characteristics reported in
this series were compatible with what has already been re-
ported in the literature. Apart from developmental delay
and intellectual disability seen in majority of our patients,
most also had coarse facies, joint restriction, respiratory
problems, hepatosplenomegaly, and abdominal hernia.
The most prevalent clinical characteristics observed in the
Fig. 7 Gel image of carrier testing for exon 8 skipping at cDNA level through gap PCR; 1:100-bp DNA ladder, 2: patient, 3: patient’s mother, 4–8:
other female family members, 9: healthy female control, 10: negative control
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HOS was facial dysmorphism followed by respiratory tract
abnormalities such as otitis media, nasal obstruction, and
enlarged tongue and adenoids. Hepatosplenomegaly, ab-
dominal hernia and joint stiffness were likewise prevalent
[12]. Similarly, in the clinical study done on 77 patients
with Mucopolysaccharidosis type II in Brazil, joint con-
tractures, macrocephaly, coarsened facial features and in-
creased abdominal volume/hepatosplenomegaly were the
most frequently reported early clinical manifestations [10].
On subspecialists’ evaluation, the most common
neurologic symptom apart from developmental delay/in-
tellectual disability was epilepsy. Behavioral abnormal-
ities were not frequently reported except for one patient
diagnosed to have autism spectrum disorder.
Error of refraction seen in this series is, indeed, a com-
mon finding in patients with Hunter syndrome [10].
Glaucoma although not frequently reported in the litera-
ture was present in 21% of the cases. In an unpublished
local study done on 15 patients with Hunter syndrome
(Roa et al., 2012, unpublished data) all were found to
have error of refraction, the most common being hyper-
opia. Other findings included strabismus, tessellated ret-
inas, pigmentary retinopathy, and large cup-to-disc
ratios. None had corneal clouding. Being one of the
most common systems affected in patients with Hunter
syndrome, early detection and management of eye prob-
lems can have a profound impact on the quality of life
especially in terms of their independence in day to day
activities thus, full ophthalmologic evaluation should be
regularly instituted.
Bronchial asthma was found in 35% of our patients
and allergic rhinitis was noted in 50% of them. These
two conditions may be due to the reactive airway disease
that happens when there is mucosal swelling, GAG ac-
cumulation, and inflammation in the nasal passages or
bronchi of patients with Hunter syndrome as what is
also similarly seen in other types of mucopolysacchari-
dosis [14]. The high incidence of airway obstruction and
sleep apnea found in this case series should alert the
physicians in suspecting and recognizing a possible
mucopolysaccharidosis when such symptoms are seen.
Cardiovascular involvement was seen in 80% of the pa-
tients, with mild valvular regurgitation being the most
common. This data is congruent with the reports from
HOS wherein the prevalence of cardiac involvement is
high among these patients and that valvular disease is
the most common finding [12, 14]. Given this, physi-
cians should aggressively assess the cardiac function of
these children and evaluate them for other reported car-
diac findings such as hypertension, arrhythmia and con-
gestive heart failure as these pose a significant cause of
morbidity and mortality [15].
In this study, there seemed to be no relation between
the severity of the cognitive impairment and the
concentration of the glycosaminoglycan excretion and
plasma iduronate-2-sulfatase assay. It was noted that the
patients with the intermediate disease even had higher
GAG excretion and lower plasma iduronate-2-sulfatase
activities compared to those with the severe phenotype.
The levels of GAG and iduronate-2-sulfatase in the pa-
tient with the attenuated phenotype also fit in the ranges
found in the group with the severe phenotype. In a study
done in Korea [16], plasma iduronate-2-sulfatase activity
in the patients with the severe type had significantly
lower values than in the attenuated type of the disease.
It was not possible to corroborate this finding in this
series as most of the patients presented with neurologic
impairments. The levels of heparan sulfate in the urine
which were previously found to correlate with the sever-
ity of Hunter syndrome [17] was not specifically deter-
mined in this cohort of patients.
The 14 mutations found in the 23 patients reflect the
genetic heterogeneity seen in Hunter syndrome. The se-
vere phenotypes found in the patients who presented
with the following mutations, p.P86L, p.R88H, p.R468Q,
and p. R468W, are in agreement with those reported in
literature [3, 18–24]. Specifically, the above mutations
have also been found in the Asian population such as in
Chinese and Japanese patients [4, 25, 26] presenting with
the severe phenotype. The published nonsense muta-
tions, p.Q75*, p.W109*, and p.R172*, were found in our
patients with severe phenotypes and were in agreement
with previous literature reports among Caucasian and
Asian patients with Hunter syndrome in terms of their
effects on phenotype [19, 20, 27–29]. Mutations introdu-
cing premature translation termination codons trigger
nonsense-mediated decay, which prevents the synthesis
of an abnormal protein, and have commonly been classi-
fied as severe mutations [4]. However, one of the pa-
tients carrying the mutation p.W109* presented with an
intermediate phenotype compared with his cousin who
carried the same mutation and manifested with a severe
phenotype. This could be explained by the imperfect
clinical correlation between patients with the same mu-
tation [3, 27].
With regard to the pathogenicity of the novel muta-
tions, the frameshift mutations caused by single-base de-
letions, p.P86Rfs*44 and p.L209Wfs*4, are both
predicted to introduce a premature stop codon down-
stream that could also trigger nonsense-mediated decay,
which is consistent with the severe phenotype. The gross
insertion in exon 9,c.1461_1462insN[710], probably led
to the destabilization of the tertiary structure of the pro-
tein resulting to a severe phenotype.
The novel missense mutations, p.C422F and p.T409R,
although probably damaging to protein function based
on the PolyPhen-2prediction algorithm (available at
http://genetics.bwh.harvard.edu/pph2/bgi.shtml,
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accessed on 31 July 2015), with scores 0.994 and 1.000,
respectively, gave rise to less severe phenotypes. The
p.C422F mutation was found in three siblings with mild
learning difficulties, while p.T409R was found in the sin-
gle patient with no cognitive dysfunction.
Conclusions
The clinical characteristics of Mucopolysaccharidosis
type II in this case series were in agreement with what
has been reported in the literature except that the age at
confirmation of diagnosis is much delayed despite earlier
onset of symptoms. Majority of the patients presented
with neurologic impairment with different grades of se-
verity. The biochemical tests showed no relation with
the consequent phenotype among the patients. The mo-
lecular analysis showed eight previously reported and six
novel mutations, the effects of which were consistent
with the severe phenotype seen in the majority of the
patients.
Our findings emphasize the need for early recognition
of Hunter syndrome among physicians and that there
should be a heightened suspicion among them for the
characteristic signs and symptoms so that delay in diag-
nosis can be avoided. Improvement in the referral sys-
tem for expert clinical evaluation as well as suitable
biochemical and molecular diagnosis will aid in the
provision of multidisciplinary care and appropriate gen-
etic counseling for the families. Likewise, in order to
maintain a better quality of life for these patients, a com-
prehensive disability assessment on the activities of daily
living (ADLs) should also be initiated so that they can
get proper help in their specific areas of difficulties and
evaluate improvements and deteriorations in important
domains over time. Availability and accessibility of en-
zyme replacement therapy and other novel drugs will
additionally be greatly beneficial to these patients and
multi-subspecialty management remains essential. The
passage of the National Rare Disease Act in March 2016
(Republic Act No. 10747, 2016) which specifies the for-
mulation of a comprehensive and sustainable health sys-
tem for orphan or rare disorders will hopefully address
the pitfalls in the diagnosis and treatment of our patients
with Hunter syndrome in the near future.
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